Skip to content
Review Open access

GWAS in Cancer Susceptibility and Therapeutic Target Discovery

Oct 2026 · Oriental Journal of Chemistry · 0 citations · 14 references

TL;DR

The current GWAS findings in several common cancers, recent methodological and analytical developments of GWAS studies that help improve the understanding of cancer biology, knowledge gained from GWAS findings for potential clinical application for therapy development, and address challenges encountered by these studies toward precision oncology are discussed.

Abstract

Genome-wide association studies (GWAS) have emerged as a revolution in the discovery of genetic determinants underlying cancer susceptibility by revealing germline variants that influence risk, progression and treatment response. In recent years, large-scale GWAS consortia have identified thousands of cancer loci in a wide variety of tumor types and importantly have shed light on inherited risk for cancer and functional elements within the noncoding genome as major contributors to oncogenic processes. These discoveries have widened the horizon of cancer genetics beyond high-penetrance mutations by establishing and recognizing for the first time ever, gaining importance of cumulative effect of common low-effect alleles and polygenic risk. In addition, the integration of GWAS data with transcriptomic, epigenomic and proteomic information has expedited functional interpretation of risk loci revealing pathways involved in DNA repair, immune modulation, cell proliferation and hormone signaling. Aside from vulnerability, GWAS-based findings have also been serving to shape medical strategies, by revealing druggable targets, biomarkers for treatment selection and risk stratification models. However, challenges including missing heritability, lack of population representation, gene-environment interactions and poor clinical translation remain. In this review, we discuss the current GWAS findings in several common cancers, recent methodological and analytical developments of GWAS studies that help improve our understanding of cancer biology, knowledge gained from GWAS findings for potential clinical application for therapy development, and address challenges encountered by these studies toward precision oncology.

Read PDF

Similar papers

Open access Sep 2026

Massively parallel functional profiling prioritizes breast cancer risk variants and implicates CCDC88C in ER-positive breast cancer

This work identified 709 variants mapping to 140 risk regions, that are associated with significant variation between REF and ALT alleles, that may influence breast cancer risk through expression of CCDC88C, which in turn could impact prognosis.

K. Mackie, H. Kemp, A. Gunnell et al. · 0 citations
Review Oct 2026

Genome-wide association studies of osteoarthritis: from genetic discovery to precision medicine.

Osteoarthritis (OA) affects more than 500 million people worldwide, yet disease-modifying therapies remain unavailable. Genome-wide association studies (GWAS) have transformed understanding of OA genetic susceptibility, progressing from early single-cohort analyses to multi-ancestry meta-analyses involving 2 million in...

Yue-Zhou Wu, Yang Hong, Xukun Lyu et al. · 0 citations
Open access Oct 2026

Large-scale association study identifies lung cancer susceptibility copy number variants and their potential functional role in genetic instability.

BACKGROUND Genome-wide association studies (GWAS) have identified numerous lung cancer susceptibility loci based on single nucleotide polymorphisms (SNPs), yet a substantial proportion of heritability remains unexplained. We therefore evaluated germline copy number variants (CNVs) as an underexplored source of genetic...

Fei-Fei Xiao, Fei Qin, Xi-Zhi Luo et al. · 0 citations
Open access Sep 2026

Cross-population genome-wide meta-analysis identifies pancreatic cancer susceptibility loci and etiologic pathways

A cross-population genome-wide association meta-analysis of 11 GWAS summary-statistic datasets comprises 20,120 pancreatic cancer cases and 1,446,192 controls genetically similar to European or East Asian reference populations refine the genetic architecture of pancreatic cancer and provide insights into candidate gene...

Shuai Yuan, Teng-Fei Li, Meng Zhang et al. · 0 citations
Open access Oct 2026

Melanoma germline genetics: immune, cancer driver, and Wnt signaling genes

Cutaneous melanoma is the deadliest skin cancer and is highly heritable, yet only 54 common risk loci have been identified. We conducted a large meta-analysis of melanoma GWAS, including 35 GWAS from 29 cohorts (69,871 cases; 1,616,233 controls) identifying 156 independent signals at 116 risk loci. We found a strong li...

G. Jayasinghe, Jian-Xin Shi, Rohit Thakur et al. · 0 citations
Review Sep 2026

Clinical Uses of Common Genetic Variants Associated with Common Diseases.

The reasons for the slow pace of the diffusion of polygenic risk scores, along with the related field of pharmacogenomics, may be useful in clinical practice for the prevention and treatment of common diseases are reviewed.

David J. Hunter, Michael Inouye · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.